Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evoke Pharma (EVOK)
NASDAQ:EVOK
Holding EVOK?
Track your performance easily
Earnings Data
Report Date
Mar 05, 2025TBA Not Confirmed
Period Ending
2024 (Q4)Consensus EPS Forecast
-$0.63Last Year’s EPS
-$7.08Same Quarter Last Year
Based on 0 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Nov 07, 2024
|% Change Since: -10.30%
|Next Earnings Date:Mar 05, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive momentum for Evoke Pharma, highlighted by significant revenue growth, strategic advancements, and promising projections for 2024. However, the net loss and increased operational expenses remain areas of concern.Company Guidance
During the fourth quarter and full year 2023 earnings call for Evoke Pharma, the company provided optimistic guidance for 2024, projecting a net revenue target of approximately $14 million, nearly tripling their 2023 performance of $5.2 million. This growth is driven by an 86% increase in new prescriptions and a 101% rise in total prescriptions dispensed year-over-year. The prescriber base expanded by 72%, with a 36% increase in the depth of prescribing. Furthermore, Evoke's strategic partnership with ASPN Pharmacy is expected to enhance distribution capabilities, improve prescription fill rates, and increase reimbursement efficiency. The company also highlighted the positive impact of GIMOTI's clinical benefits, including a significant reduction in hospitalizations and ER visits, and emphasized their commitment to expanding access and optimizing patient care.Doubling of Net Revenue
Evoke Pharma reported doubling their net revenue for GIMOTI over the last year with a notable increase in total prescriptions dispensed by 101% year-over-year.
GIMOTI's Clinical and Economic Benefits
Studies show a 68% reduction in hospitalizations and a 60% reduction in ER visits for patients using GIMOTI compared to oral metoclopramide, demonstrating significant healthcare cost savings.
Expanded Prescriber Base
The number of new prescriptions grew by 86%, and the prescriber base increased by 72%, indicating a growing acceptance of GIMOTI among healthcare providers.
Strategic Partnership with ASPN
Transitioning pharmacy services to ASPN enhanced patient access and streamlined services, resulting in a 22% improvement in new prescription fills.
Projected Revenue Growth for 2024
Evoke Pharma aims for a projected net revenue of approximately $14 million, nearly tripling their 2023 performance.
---
EVOK Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
EVOK Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Nov 07, 2024 | $5.65 | $5.65 | 0.00% |
| Aug 13, 2024 | $5.69 | $5.74 | +0.88% |
| May 14, 2024 | $5.64 | $5.62 | -0.35% |
| Mar 14, 2024 | $8.10 | $7.44 | -8.15% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Evoke Pharma (EVOK) report earnings?
Evoke Pharma (EVOK) is schdueled to report earning on Mar 05, 2025, TBA Not Confirmed.
What is Evoke Pharma (EVOK) earnings time?
Evoke Pharma (EVOK) earnings time is at Mar 05, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is EVOK EPS forecast?
EVOK EPS forecast for the fiscal quarter 2024 (Q4) is -$0.63.
---